Vidacare‘s EZ-IO injector has now received expanded European approval for “an extended dwell time of no greater than 72 hours for intraosseous (inside the bone) vascular access placements and for IO insertion in pediatric patients in the distal femur.” Previous approval was indicated for a maximum dwell time of 24 hours.
Vidacare’s EZ-IO Intraosseous Infusion System, the market leader in IO technology, provides immediate vascular access for patients in multiple clinical settings, using the intraosseous (inside the bone) space. The EZ-IO is used by 90 percent of US advanced life support ambulances and over half of US Emergency Departments, as well as the US Military.
Press release: European Union Expands CE Mark Approval to Vidacare Corporation’s EZ-IO® Intraosseous Infusion System…
Product page: EZ-IO® Intraosseous Infusion System…
Flashback: The EZ-IO Product System Gets Energized…